Preview: Codexis's Earnings
Codexis (NASDAQ:CDXS) is preparing to release its quarterly earnings on Wednesday, 2026-03-11. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Codexis to report an earnings per share (EPS) of $-0.04.
Investors in Codexis are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Overview of Past Earnings
Last quarter the company missed EPS by $0.08, which was followed by a 16.95% drop in the share price the next day.
Here's a look at Codexis's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.14 | -0.16 | -0.21 | -0.02 |
| EPS Actual | -0.22 | -0.16 | -0.25 | -0.13 |
| Price Change % | -16.95 | 1.64 | 1.62 | -22.65 |
Market Performance of Codexis's Stock
Shares of Codexis were trading at $1.25 as of March 09. Over the last 52-week period, shares are down 54.35%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
Unveiling the Story Behind Codexis
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
Financial Insights: Codexis
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Codexis's financials over 3 months reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately -32.98% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Codexis's net margin is impressive, surpassing industry averages. With a net margin of -228.05%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Codexis's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -41.66%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Codexis's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -14.96%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.78.
To track all earnings releases for Codexis visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.